NCT00242216View on ClinicalTrials.gov

"The Once A Day Protease Inhibitor Regimens"

PHASE4CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
HIV Infections
Interventions
DRUG

ritonavir-boosted atazanavir

100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.

DRUG

ritonavir-boosted fosamprenavir

100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.

Trial Locations (1)

77009

Thomas Street Health Center, Houston

All Listed Sponsors
lead

The University of Texas Health Science Center, Houston

OTHER

NCT00242216 - "The Once A Day Protease Inhibitor Regimens" | Biotech Hunter | Biotech Hunter